US › Healthcare

Ensysce Biosciences Inc (ENSC)

US · Healthcare · Biotechnology

$0.38+37.17%

Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue

$960,999

Revenue YoY

-27.2%

Net profit

$-3.6M

Profit YoY

-82.8%

EPS

$-0.52

EPS estimate

$-0.73

Net margin

-370.1%

EPS came in at -0.52 against a street estimate of -0.73 — a beat of 28.8%.

Key statistics

Market cap

$3.9M

Forward P/E

0.9

P/B

0.86

Book value

$-0.04

EPS (TTM)

$-3.11

52-week high

$2.75

52-week low

$0.23

50-day MA

$0.28

200-day MA

$0.82

Beta

0.79

Analyst view

Analysts rate Ensysce Biosciences Inc a buy (1 buy, 0 hold, 0 sell out of 1) with an average price target of $16.45.

Shareholding

Insiders

0.06%

Institutions

3.31%

Largest institutional holders

Fund	Stake
Adage Capital Partners Gp LLC	0.97%
Perceptive Advisors LLC	0.56%
Geode Capital Management, LLC	0.48%
Citadel Advisors Llc	0.37%
XTX Topco Ltd	0.16%
Vanguard Fiduciary Trust Co	0.16%
Jane Street Group LLC	0.09%
Virtu Financial LLC	0.09%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Ensysce Biosciences Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Novo Nordisk A/S Amgen Inc Abbott Laboratories Gilead Sciences Inc

Data updated 2026-08-05.